<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2047487312467876</article-id>
<article-id pub-id-type="publisher-id">10.1177_2047487312467876</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Working together in cardiovascular prevention: the common mission of the <italic>European Heart Journal</italic> and the <italic>European Journal of Preventive Cardiology</italic></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lüscher</surname><given-names>Thomas F</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312467876">1</xref>
<xref ref-type="corresp" rid="corresp1-2047487312467876"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Landmesser</surname><given-names>Ulf</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312467876">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ruschitzka</surname><given-names>Frank</given-names></name>
<xref ref-type="aff" rid="aff1-2047487312467876">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grobbee</surname><given-names>Diederick E</given-names></name>
<xref ref-type="aff" rid="aff2-2047487312467876">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2047487312467876"><label>1</label>Editorial Office, European Heart Journal, Zurich Heart House, Moussonstreet 4, 8091 Zürich, Switzerland.</aff>
<aff id="aff2-2047487312467876"><label>2</label>Editorial Office, European Journal of Preventive Cardiology, University Medical Center, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands.</aff>
<author-notes>
<corresp id="corresp1-2047487312467876">Thomas F Lüscher, Editor-in-Chief, European Heart Journal, Zurich Heart House, Moussonstreet 4, 8091 Zürich, Switzerland Email: <email>cardiotfl@gmx.ch</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>1217</fpage>
<lpage>1226</lpage>
<permissions>
<copyright-statement>© The European Society of Cardiology 2012 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="sec1-2047487312467876"><title>Prevention in the first place</title>
<p>Preventing is better than treating a disease – no one would disagree. Nevertheless, prevention has long remained the Cinderella of cardiology. The scientific community was so impressed by the heroism of pioneering surgeons and interventionalists, the sophistication of electrophysiologist, the novel devices, and amazing modern imaging technologies that prevention has a hard time to get the attention it deserves. This is surprising, since prevention has already started with the awakening of medicine as a scientific discipline: indeed, Edward Jenner (1749–1823) introduced vaccination against smallpox already in the late 18th century and hygiene made its way into everyday life as a first preventive measure already in the 19th century. Yet cardiovascular medicine has taken more time to have its value recognized.</p>
<p>Rudolf Virchow (1821–1902; <xref ref-type="fig" rid="fig1-2047487312467876">Figure 1</xref>), the eminent German physician and politician, set the stage by stating that atherosclerosis is an inflammation induced by cholesterol,<sup><xref ref-type="bibr" rid="bibr1-2047487312467876">1</xref>,<xref ref-type="bibr" rid="bibr2-2047487312467876">2</xref></sup> a concept that was experimentally proven by Nikolai Nikolaievich Anitchkow (1885–1964; <xref ref-type="fig" rid="fig1-2047487312467876">Figure 1</xref>), the Russian military physician who first fed rabbits with a high-fat diet only to discover that such an intervention indeed produced lipid plaques in the aorta of these animals.<sup><xref ref-type="bibr" rid="bibr3-2047487312467876">3</xref></sup> Independently, in 1916, the Dutch physician Cornelis D De Langen published an article titled ‘Cholesterol metabolism and racial pathology’<sup><xref ref-type="bibr" rid="bibr4-2047487312467876">4</xref></sup> (<xref ref-type="fig" rid="fig1-2047487312467876">Figure 1</xref>). He noted that the cholesterol levels of Dutch immigrants in the former Dutch Indies were approximately twice as high as those of native Javanese. He hypothesized that these differences were due to differences in diet and that hypercholesterolaemia was associated with metabolic diseases such as atherosclerosis, diabetes, obesity, and nephritis.<sup><xref ref-type="bibr" rid="bibr5-2047487312467876">5</xref></sup>
<fig id="fig1-2047487312467876" position="float"><label>Figure 1.</label><caption><p>Pioneers of preventive medicine: Edward Jenner (1749–1823; left) /Rudolf Virchow (1821–1902; middle left), Nikolai Nikolaievich Anitchkow (1885–1964; middle right) and William Kannel (1923–2011; right).</p></caption><graphic xlink:href="10.1177_2047487312467876-fig1.tif"/></fig></p>
<p>The Framingham Heart Study, starting in 1948, then embarked in testing the concept in residents of this suburb of Boston, initially under the leadership of Thomas R Dawber<sup><xref ref-type="bibr" rid="bibr6-2047487312467876">6</xref></sup> followed by William Kannel<sup><xref ref-type="bibr" rid="bibr7-2047487312467876">7</xref></sup> in 1966 (<xref ref-type="fig" rid="fig1-2047487312467876">Figure 1</xref>). Soon it became obvious that age, smoking, high cholesterol, blood pressure, and diabetes were strong predictors of major cardiovascular events. With this evidence at hand, preventive measures became an effective option.</p>
<p>In the 1960s, the surgeon general warned the public of the health hazards of smoking and slowly, but surely the number of subjects addicted to that habit has decreased, particularly most recently with the introduction of anti-smoking legislation in many countries. At the same time, antihypertensive drugs were developed and introduced into clinical practice.<sup><xref ref-type="bibr" rid="bibr8-2047487312467876">8</xref></sup> With an increasing number of trials documenting the benefits of blood pressure lowering, the use of diuretics, beta-blockers, calcium antagonists, and inhibitors of the renin–angiotension–aldosterone system became increasingly widespread.<sup><xref ref-type="bibr" rid="bibr9-2047487312467876">9</xref></sup> Of note, the decline in the incidence of stroke in many Western countries is a major success of preventive cardiovascular medicine.<sup><xref ref-type="bibr" rid="bibr10-2047487312467876">10</xref></sup> With the advent of statins in the 1980s, effective lowering of low-density lipoprotein levels also became an option.<sup><xref ref-type="bibr" rid="bibr11-2047487312467876">11</xref></sup> Thus, preventive cardiology today has an impressive armamentarium of drugs at hand to prevent cardiovascular diseases. Although life-style changes have also been shown to reduce cardiovascular risk, their implementation in the general population proved to be more difficult.<sup><xref ref-type="bibr" rid="bibr12-2047487312467876">12</xref></sup> Indeed, the apparently unstoppable increase in body weight in the Western world with a steady increase in incidence and prevalence of diabetes is an ominous sign of our inability to use preventive measures effectively in everyday life.<sup><xref ref-type="bibr" rid="bibr13-2047487312467876">13</xref></sup> Thus, in spite of its remarkable successes, cardiovascular prevention has a long way to go.</p>
</sec>
<sec id="sec2-2047487312467876"><title>Publishing in cardiovascular medicine</title>
<p>It is the mission of the European Society of Cardiology (ESC) to reduce the burden of cardiovascular disease in Europe. To that end, education and research is its major strategy. Hence, the ESC started its first journal in 1980<sup><xref ref-type="bibr" rid="bibr14-2047487312467876">14</xref></sup> under the leadership of Desmond Julian with a small number of submissions and no impact factor. Over the last 30 years under the leadership of four succeeding editors (i.e. Henry Kulbertus, Kim Fox, Frans van de Werf and Thomas F Lüscher<sup><xref ref-type="bibr" rid="bibr15-2047487312467876">15</xref></sup>) the <italic>European Heart Journal</italic> has made it to centre stage in cardiovascular medicine.<sup><xref ref-type="bibr" rid="bibr16-2047487312467876">16</xref></sup> Indeed, the submissions have increased steadily over the years and are expected to reach around 3800 this year. As a consequence, the acceptance rate has decreased to around 10% and its impact factor has steadily risen to 10.5.<sup><xref ref-type="bibr" rid="bibr17-2047487312467876">17</xref></sup></p>
<p>But it is not just the main journal that has contributed to the success of the mission of the European Society of Cardiology; rather, a growing number of subspecialty journals has been part of it as well. Indeed, the rapidly evolving fields of cardiology, among them preventive cardiology, have started to become true subspecialties with a need for both specific journals and proper annual meetings focussing on their specific area of interest. The first ESC subspecialty journal, <italic>Europace</italic>, was introduced in 1999, followed in the same year by the <italic>European Journal of Heart Failure</italic>. In response to the obvious importance of, as well as the rising interest in, cardiovascular prevention and the increasingly evidence-based management of it, the ESC established a subspecialty journal on this subject in 2003 under the name of <italic>European Journal of Cardiovascular Prevention and Rehabilitation</italic>. The founding editors, David Wood and Hugo Saner, got the Journal off the ground, starting on the basis of the then-existing <italic>Journal of Cardiovascular Risk</italic>.<sup><xref ref-type="bibr" rid="bibr18-2047487312467876">18</xref></sup> In 2008, Pantaleo Gianuzzi and Diederick E Grobbee took over as Senior Joint Editors and developed the Journal further. Since May 2010, Professor Grobbee has been acting as main Editor-in-Chief, now under its new name, <italic>European Journal of Preventive Cardiology</italic> (Figures <xref ref-type="fig" rid="fig2-2047487312467876">2</xref> and <xref ref-type="fig" rid="fig3-2047487312467876">3</xref>). In its first year, three issues of the Journal appeared, but since 2004 it has been published on a bi-monthly basis. The manuscript submission has steadily increased, from 318 in 2008 to an expected 540 in 2012 (<xref ref-type="fig" rid="fig4-2047487312467876">Figure 4A</xref>), as has the impact factor to the current rating of 2.634 (<xref ref-type="fig" rid="fig4-2047487312467876">Figure 4B</xref>).
<fig id="fig2-2047487312467876" position="float"><label>Figure 2.</label><caption><p>The editors-in-chief of the <italic>European Journal of Preventive Cardiology</italic> (formerly <italic>European Journal of Cardiovascular Prevention and Rehabilitation</italic>): Hugo Saner, (Switzerland) and John Wood (UK) (2003–2008), Pantaleo Gianuzzi (Italy) (2008–2010), and Diederick E Grobbee (The Netherlands) (2008–today).</p></caption><graphic xlink:href="10.1177_2047487312467876-fig2.tif"/></fig>
<fig id="fig3-2047487312467876" position="float"><label>Figure 3.</label><caption><p>The ESC journal family with their respective impact factors 2011.</p></caption><graphic xlink:href="10.1177_2047487312467876-fig3.tif"/></fig>
<fig id="fig4-2047487312467876" position="float"><label>Figure 4.</label><caption><p>Development of manuscript submissions (A) and the impact factor (B) of the <italic>European Journal of Preventive Cardiology</italic> (formerly <italic>European Journal of Cardiovascular Prevention and Rehabilitation</italic>) over time (data from Oxford University Press 2012).</p></caption><graphic xlink:href="10.1177_2047487312467876-fig4.tif"/></fig></p>
</sec>
<sec id="sec3-2047487312467876"><title>Guidelines for clinical practice</title>
<p>For the implementation of knowledge into clinical practice, guidelines by credible international bodies are crucial. Hence, in line with its mission, the European Society of Cardiology has published numerous guidelines on the management of cardiovascular diseases. In 2011 alone, the <italic>European Heart Journal</italic> published guidelines on the management of dyslipidaemias (together with the European Atherosclerosis Society),<sup><xref ref-type="bibr" rid="bibr11-2047487312467876">11</xref></sup> on the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation,<sup><xref ref-type="bibr" rid="bibr19-2047487312467876">19</xref></sup> the management of cardiovascular diseases during pregnancy,<sup><xref ref-type="bibr" rid="bibr20-2047487312467876">20</xref></sup> and on the diagnosis and treatment of peripheral artery diseases<sup><xref ref-type="bibr" rid="bibr21-2047487312467876">21</xref></sup> as well as preoperative risk,<sup><xref ref-type="bibr" rid="bibr22-2047487312467876">22</xref></sup> and in this year on cardiovascular disease prevention in clinical practice,<sup><xref ref-type="bibr" rid="bibr23-2047487312467876">23</xref></sup> a novel statement on the universal definition of myocardial infarction,<sup><xref ref-type="bibr" rid="bibr24-2047487312467876">24</xref></sup> as well as guidelines on valvular heart disease,<sup><xref ref-type="bibr" rid="bibr25-2047487312467876">25</xref></sup> heart failure,<sup><xref ref-type="bibr" rid="bibr26-2047487312467876">26</xref></sup> acute myocardial infarction,<sup><xref ref-type="bibr" rid="bibr27-2047487312467876">27</xref></sup> and a focused update on atrial fibrillation.<sup><xref ref-type="bibr" rid="bibr28-2047487312467876">28</xref></sup> Since 2003,<sup><xref ref-type="bibr" rid="bibr29-2047487312467876">29</xref></sup> in preventive cardiology, guidelines have been published simultaneously in the <italic>European Heart Journal</italic> and the <italic>European Journal of Preventive Cardiology</italic>.</p>
<sec id="sec4-2047487312467876"><title>Influence and impact</title>
<p>Due to their importance for everyday practice, guidelines are highly used and cited. Indeed, the downloads of many guidelines surpass their citations documenting their influence on physicians behaviour.<sup><xref ref-type="bibr" rid="bibr30-2047487312467876">30</xref></sup> Of note, even the best-cited recent ESC guidelines such as the one on the diagnosis and treatment of pulmonary hypertension<sup><xref ref-type="bibr" rid="bibr31-2047487312467876">31</xref></sup> have been downloaded much more often (i.e. 28,600 cumulative downloads) than cited (252 citations). Similarly striking is this trend for the guidelines on the diagnosis and management of syncope<sup><xref ref-type="bibr" rid="bibr32-2047487312467876">32</xref></sup> (130 citations and some 21,800 downloads) and even more impressively for the guidelines for prevention, diagnosis, and treatment of infective endocarditis<sup><xref ref-type="bibr" rid="bibr33-2047487312467876">33</xref></sup> (119 citations and an impressive 48,500 downloads).</p>
</sec>
</sec>
<sec id="sec5-2047487312467876"><title>The best of prevention in the European Heart Journal</title>
<p>The <italic>European Heart Journal</italic> is highly interested in submissions related to cardiovascular prevention and has devoted an entire focus issue on prevention<sup><xref ref-type="bibr" rid="bibr34-2047487312467876">34</xref></sup> this year and reviews on fish oil<sup><xref ref-type="bibr" rid="bibr35-2047487312467876">35</xref></sup> and nutrition.<sup><xref ref-type="bibr" rid="bibr36-2047487312467876">36</xref></sup></p>
<sec id="sec6-2047487312467876"><title>Exercise and sport</title>
<p>A secondary analysis on sedentary behaviour of INTERHEART<sup><xref ref-type="bibr" rid="bibr37-2047487312467876">37</xref></sup> confirmed an earlier well-cited study on sedentary time and cardiovascular biomarkers from the large NHANES 2003–2006 study.<sup><xref ref-type="bibr" rid="bibr38-2047487312467876">38</xref></sup> Thus, today, it is well established that a sedentary life style unfavourably affects high-density lipoprotein (HDL) cholesterol, triglycerides, C-reactive protein, and insulin resistance and thus augments the risk of future acute coronary syndromes. On the other hand, although regular exercise and sports are important life-style measures in prevention, exercise, and sport are also associated with an increased risk of myocardial infarction and sudden cardiac death.<sup><xref ref-type="bibr" rid="bibr39-2047487312467876">39</xref></sup> Prevention is the only option,<sup><xref ref-type="bibr" rid="bibr40-2047487312467876">40</xref></sup> i.e. pre-competition screening such as that pioneered by the Italians. For pre-competition screening, the recommendations for interpretation of 12-lead electrocardiogram in the athlete of the Section for Sports Cardiology of the European Association of Cardiovascular Prevention and Rehabilitation<sup><xref ref-type="bibr" rid="bibr41-2047487312467876">41</xref></sup> are thus of utmost importance and hence highly cited. For every ECG abnormality, the position paper focused on the ensuing clinical workup required. Still, there remains a need for further refinement of risk prediction in athletes and those engaged in leisurely sports.<sup><xref ref-type="bibr" rid="bibr42-2047487312467876">42</xref></sup></p>
</sec>
<sec id="sec7-2047487312467876"><title>The role of body fat</title>
<p>The best-cited prevention paper published in the <italic>European Heart Journal</italic> in the last years, with 58 citations, was an analysis of the Framingham study focussing on the association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden.<sup><xref ref-type="bibr" rid="bibr43-2047487312467876">43</xref></sup> Although visceral abdominal fat is a well-recognized cardiovascular risk factor, the fact that pericardial fat further contributes to cardiovascular risk had not been reported so far. Interestingly, pericardial fat turned out to be as predictive as visceral abdominal fat.</p>
</sec>
<sec id="sec8-2047487312467876"><title>Inflammation and atherosclerosis</title>
<p>Chronic inflammation is a major driver of the atherosclerotic process.<sup><xref ref-type="bibr" rid="bibr44-2047487312467876">44</xref></sup> In the focus issue on prevention, an editorial by Eugene Braunwald<sup><xref ref-type="bibr" rid="bibr45-2047487312467876">45</xref></sup> and the related paper by Peter Sever on C-reactive protein in the ASCOT trial<sup><xref ref-type="bibr" rid="bibr46-2047487312467876">46</xref></sup> tried to settle controversial issues on that subject. A highly cited paper on severe psoriasis and cardiovascular risk provided further evidence that chronic inflammation, even if involving the skin and joints, contributes to cardiovascular mortality.<sup><xref ref-type="bibr" rid="bibr47-2047487312467876">47</xref></sup></p>
</sec>
<sec id="sec9-2047487312467876"><title>HDL cholesterol</title>
<p>Within the preventive community, great hopes rested on drugs effectively increasing HDL cholesterol levels. Therefore, cholesterol ester protein (CETP) inhibition was highly welcomed as a novel therapeutic strategy. Unfortunately, the first CETP inhibitor, torcetrapib, increased rather than decreased mortality<sup><xref ref-type="bibr" rid="bibr48-2047487312467876">48</xref></sup> most likely due to its off-target effects on eNOS, endothelin-1, aldosterone, and blood pressure.<sup><xref ref-type="bibr" rid="bibr49-2047487312467876">49</xref></sup> Similarly, no benefits on carotid arterial thickness could be noted.<sup><xref ref-type="bibr" rid="bibr50-2047487312467876">50</xref></sup> A recent paper in the <italic>Lancet</italic> based on Mendelian randomization further questioned the causal role of HDL in cardioprotection.<sup><xref ref-type="bibr" rid="bibr51-2047487312467876">51</xref></sup> Of note, the dal-Vessel trial with the novel CETP inhibitor dalcetrapib published as a fast track paper in the <italic>European Heart Journal</italic> showed that this novel molecule did not affect blood pressure, but effectively increased HDL cholesterol;<sup><xref ref-type="bibr" rid="bibr52-2047487312467876">52</xref></sup> yet contrary to the expectations, endothelial function did not improve during chronic therapy with dalcetrapib.<sup><xref ref-type="bibr" rid="bibr53-2047487312467876">53</xref></sup> The latter finding was the most disconcerting because a well-cited study, by Rubinstein et al.,<sup><xref ref-type="bibr" rid="bibr54-2047487312467876">54</xref></sup> on endothelial dysfunction using non-invasive peripheral arterial tonometry confirmed in 270 patients followed over 7 years that such functional vascular changes are truly associated with a higher event rate. And indeed, in March 2012, Roche, the manufacturer of dalcetrapib, had to abruptly stop the development of their novel drug due to futility in the large dal-outcome trial.<sup><xref ref-type="bibr" rid="bibr55-2047487312467876">55</xref></sup> It is therefore doubtful whether other CETP inhibitors such as anacetrapib will prove to be effective for patients with low HDL cholesterol, as discussed by John Chapman et al.<sup><xref ref-type="bibr" rid="bibr56-2047487312467876">56</xref></sup> It may well be that the suggestion made by the European Atherosclerosis Society Consensus Panel, that in patients with cardiometabolic abnormalities at low-density lipoprotein cholesterol goal the elevated levels of triglyceride-rich lipoproteins might represent a more promising therapeutic target<sup><xref ref-type="bibr" rid="bibr57-2047487312467876">57</xref></sup> than HDL cholesterol, may turn out to be visionary, although trials with fibrates and niacin have not convincing so far.</p>
</sec>
<sec id="sec10-2047487312467876"><title>Other risk factors</title>
<p>Homocysteine, and folate even more, is controversial as a risk factor rather than HDL cholesterol.<sup><xref ref-type="bibr" rid="bibr58-2047487312467876">58</xref></sup> Indeed, large interventional trials with folate fortification could not demonstrate a benefit of lowering homocysteine. In a highly cited review, Antoniades et al.<sup><xref ref-type="bibr" rid="bibr59-2047487312467876">59</xref></sup> provided molecular explanations why this approach to lower homocysteine might not work. On the other hand, a so-far unrecognized risk factor, i.e. sleep duration, has attracted a lot of press coverage upon its publication in the <italic>European Heart Journal</italic>. Of note, Cappuccio et al.<sup><xref ref-type="bibr" rid="bibr60-2047487312467876">60</xref></sup> found that short as well as long sleep habits are predictive of future cardiovascular events.</p>
</sec>
</sec>
<sec id="sec11-2047487312467876"><title>Sharing and transferring manuscripts</title>
<p>With the new editorship of the <italic>European Heart Journal</italic>, the ESC journal family has become more closely linked (<xref ref-type="fig" rid="fig5-2047487312467876">Figure 5A</xref>). A manuscript transfer system was put in place allowing for transfer of papers from the main journal to the <italic>European Journal of Preventive Cardiology</italic> and other subspecialty journals. With an acceptance rate of 11%, the editors of the <italic>European Heart Journal</italic> are forced to reject valuable papers, although some of them just did not make it due to space limitations, while others might be too specialized or too technical for the general reader. The manuscript transfer allows the rescue of papers that are better suited for subspecialty journals. The subspecialty editor, in this instance Diederick E Grobbee, receives flagged manuscript with the reviews obtained by the <italic>European Heart Journal</italic> and is free to offer re-submission of a revised paper based on the available reviews. The authors will then have to decide whether they are ready to do so.
<fig id="fig5-2047487312467876" position="float"><label>Figure 5.</label><caption><p>(A) The growing ESC journal family today works closely together and now also includes <italic>EuroIntervention</italic>, the official journal of the <italic>European Association of Percutaneous Cardiac Interventions</italic> (EAPCI) and it has just welcomed the <italic>European Heart Journal</italic>: <italic>Acute Cardiac Care</italic>, the official journal of the new <italic>European Association of Acute Cardiac Care</italic>. Altogether, therefore, nine journals covering the entire spectrum of cardiovascular medicine are part of the ESC journal family. (B) Results of the manuscript transfer in the last 3 years from the <italic>European Heart Journal</italic> to the different subspecialty journals of the ESC journal family, and the <italic>European Journal of Preventive Cardiology</italic> (red column) in particular (data from Oxford University Press, 2012).</p></caption><graphic xlink:href="10.1177_2047487312467876-fig5.tif"/></fig></p>
<p>Since the introduction of the manuscript transfer system, around 2000 papers have been flagged for transfer to different subspecialty journals (<xref ref-type="fig" rid="fig5-2047487312467876">Figure 5B</xref>), most of them (i.e. 625 or roughly 30%) to the <italic>European Journal of Heart Failure</italic> and the <italic>European Journal of Preventive Cardiology</italic>. In total, 1200, or around 60% of the manuscripts offered, have been accepted pending revision by the subspecialty editors. Around half of those were resubmitted in a revised version to the subspecialty journal. Eventually, 60% of the transferred manuscripts were accepted and published. Of note, the author’s acceptance was largely determined by the impact factor of the subspecialty journal (<xref ref-type="fig" rid="fig4-2047487312467876">Figure 4</xref>). Indeed, author acceptance averaged 80% with the <italic>European Journal of Heart Failure</italic> (IF 4.896), but only 50% with the <italic>European Journal of Preventive Cardiology</italic> (IF 2.634), and even lower with <italic>Europace</italic> (40%; IF 1.980). It is hoped and part of the strategy of the ESC Publications Committee that with the manuscript transfer system, the impact factor of the subspecialty journals will also raise steadily.</p>
</sec>
<sec id="sec12-2047487312467876"><title>The strategy of the European Journal of Preventive Cardiology</title>
<p>In 2012 the new name and face of the journal of the European Association for Cardiovascular Rehabilitation and Prevention was introduced: the <italic>European Journal of Preventive Cardiology</italic>.<sup><xref ref-type="bibr" rid="bibr61-2047487312467876">61</xref></sup> Preventive cardiology encompasses all those activities aimed at preventing the occurrence of cardiovascular disease and improving prognosis once clinical events have been diagnosed. Preventive cardiology is not restricted to the boundaries of the hospital ward but increasingly regards high-risk groups in the population or even the population at large. Consequently, its practitioners and researchers can be found in the hospital, in primary care, and in public health. The Journal embraces all scientific, clinical, and public health contributions that address the causes and prevention of cardiovascular disease, as well as cardiovascular rehabilitation, sports cardiology, and exercise physiology. It is uniquely positioned as the highest-ranking journal for exchange of scientific and practical knowledge on cardiovascular prevention. It is increasingly recognized that the largest burden of cardiovascular disease afflicts lower- and middle-income countries and emerging economies.<sup><xref ref-type="bibr" rid="bibr62-2047487312467876">62</xref></sup> The editorial board of the Journal is expanding to assure adequate representation of these regions of the world, and high-quality manuscripts reporting on global aspects of cardiovascular disease are particularly welcome.<sup><xref ref-type="bibr" rid="bibr63-2047487312467876">63</xref></sup> Another role for the Journal is to present the most recent guidelines and recommendations on preventive cardiology, notably the ESC guidelines on cardiovascular disease prevention in clinical practice,<sup><xref ref-type="bibr" rid="bibr64-2047487312467876">64</xref></sup> jointly published with the <italic>European Heart Journal</italic>. Other recent examples include a comprehensive overview of all aspects of physical activity.<sup><xref ref-type="bibr" rid="bibr65-2047487312467876">65</xref></sup> Guidelines are put in perspective in editorials and guideline implementation and its barriers are examined across the globe.<sup><xref ref-type="bibr" rid="bibr66-2047487312467876">66</xref></sup> The Journal does not limit its interest to life-style factors in prevention but encourages publication of results from randomized drug trials in primary and secondary prevention.<sup><xref ref-type="bibr" rid="bibr67-2047487312467876">67</xref></sup> More recently, the Journal has created space for sponsored supplements addressing innovative treatments or new diagnostic methods.<sup><xref ref-type="bibr" rid="bibr68-2047487312467876">68</xref>,<xref ref-type="bibr" rid="bibr69-2047487312467876">69</xref></sup> Supplements follow the regular review process. The Journal is also open to design papers on major cardiovascular prevention studies.<sup><xref ref-type="bibr" rid="bibr70-2047487312467876">70</xref></sup> In its brief period of existence, evolving from the <italic>Journal of Cardiovascular Risk</italic> to the <italic>European Journal of Preventive Cardiology</italic>, the Journal has grown to an indispensable platform for scientific exchange and discourse on cardiovascular prevention and an asset to the ESC journal family,</p>
</sec>
<sec id="sec13-2047487312467876"><title>The best of the European Journal of Preventive Cardiology</title>
<p>The top ten most-cited papers in the <italic>European Journal of Preventive Cardiology</italic> and its predecessor include position papers, surveys, and reviews, but also original research papers.</p>
<p>EUROASPIRE III, a survey on the life style, risk factors, and use of cardioprotective drug therapies in coronary patients involving 22 European countries,<sup><xref ref-type="bibr" rid="bibr71-2047487312467876">71</xref></sup> is among the most cited, with 149 citations in scientific literature. Its sister paper on the management of cardiovascular risk factors in asymptomatic high-risk patients in general practice has also had a lot of attention (26 citations).<sup><xref ref-type="bibr" rid="bibr72-2047487312467876">72</xref></sup> Both surveys showed that preventive measures and life-style changes in patients at risk is still suboptimal in Europe. Not surprisingly, the position paper from the Cardiac Rehabilitation section of the European Association of Cardiovascular Prevention and Rehabilitation on secondary prevention was similarly well cited.<sup><xref ref-type="bibr" rid="bibr73-2047487312467876">73</xref></sup> Telehealth has been introduced to improve secondary prevention; a well-cited systematic review published in 2009 (24 citations) confirmed the effectiveness of this intervention.<sup><xref ref-type="bibr" rid="bibr74-2047487312467876">74</xref></sup></p>
<p>Exercise testing and physical activity are major topics in prevention and rehabilitation. Accordingly, the report from the Exercise Physiology section of the European Association of Cardiovascular Prevention and Rehabilitation on standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients has been considerably cited,<sup><xref ref-type="bibr" rid="bibr75-2047487312467876">75</xref></sup> as was a review of the methodologies for the assessment of physical activity, again published by the Exercise Physiology Section.<sup><xref ref-type="bibr" rid="bibr76-2047487312467876">76</xref></sup> Of note, physical inactivity in patients with rheumatoid arthritis has also been associated with a worse cardiovascular risk profile, as reported by Metsios et al. in 2009 (20 citations).<sup><xref ref-type="bibr" rid="bibr77-2047487312467876">77</xref></sup></p>
<p>As in the main journal, HDL cholesterol and its contribution to cardiovascular risk is a major issue. Of note, in a well-cited paper, Cooney et al. showed that in a large cohort of more than 50,000 patients, HDL cholesterol resulted only in a modest improvement of cardiovascular risk estimation.<sup><xref ref-type="bibr" rid="bibr78-2047487312467876">78</xref></sup> HDL cholesterol is also of interest in diabetics, patients who generally have low plasma levels of this lipoprotein.<sup><xref ref-type="bibr" rid="bibr79-2047487312467876">79</xref></sup> Besides coronary artery disease, renal failure is a major issue in these patients, as outlined by a well-cited review published in the Journal in 2010.<sup><xref ref-type="bibr" rid="bibr80-2047487312467876">80</xref></sup></p>
<p>Finally, HIV infection has become a concern; indeed, in a prospective multinational cohort involving more than 20,000 patients, risk prediction appeared more accurate when considering exposure to antiretroviral drugs in addition to classical cardiovascular risk factors than usual risk models.<sup><xref ref-type="bibr" rid="bibr81-2047487312467876">81</xref></sup></p>
</sec>
<sec id="sec14-2047487312467876"><title>Future perspectives</title>
<p>In short, the ESC journal family is on the move and it is hoped that it will grow the prime educational product in cardiovascular medicine as has the Annual Congress in its own field: <italic>l’union fait la force</italic> is our current strategy that hopefully will pay out as much in the future as it already has in the last years. And indeed, knowledge implementation remains the major challenge in prevention.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-2047487312467876"><label>1</label><citation citation-type="other"><comment>Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt: AM Meidinger, 1856. 478, fn</comment>.</citation></ref>
<ref id="bibr2-2047487312467876"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Virchow</surname><given-names>R</given-names></name></person-group>. <article-title>Erinnerungsblatter</article-title>. <source>Arch Path Anat Physiol</source> <year>1852</year>; <volume>4</volume>: <fpage>541</fpage>–<lpage>548</lpage>.</citation></ref>
<ref id="bibr3-2047487312467876"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anitschkow</surname><given-names>N</given-names></name><name><surname>Chalatow</surname><given-names>S</given-names></name></person-group>. <article-title>Ueber experimentelle Cholester-insteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse</article-title>. <source>Zentrbl Allg Pathol Pathol Anat</source> <year>1913</year>; <volume>24</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation></ref>
<ref id="bibr4-2047487312467876"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Langen</surname><given-names>CD</given-names></name></person-group>. <article-title>Cholesterol metabolism and racial pathology [in Dutch]</article-title>. <source>Geneesk Tijdschr Nederl Indië</source> <year>1916</year>; <volume>56</volume>: <fpage>1</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr5-2047487312467876"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kromhout</surname><given-names>D</given-names></name><name><surname>Menotti</surname><given-names>A</given-names></name><name><surname>Kesteloot</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies</article-title>. <source>Circulation</source> <year>2002</year>; <volume>105</volume>: <fpage>893</fpage>–<lpage>898</lpage>.</citation></ref>
<ref id="bibr6-2047487312467876"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dawber</surname><given-names>TR</given-names></name><name><surname>Meadors</surname><given-names>GF</given-names></name><name><surname>Moore</surname><given-names>FE</given-names><suffix>Jr</suffix></name></person-group><collab>National Heart Institute, National Institutes of Health, Public Health Service, Federal Security Agency, Washington, DC, Epidemiological approaches to heart disease: the Framingham study presented at a joint session of the epidemiology, health officers, medical care, and statistics sections of the American Public Health Association, at the seventy-eighth annual meeting in St</collab>. <article-title>Louis, Mo, 1950</article-title>. <source>Am J Public Health Nations Health</source> <year>1951</year>; <volume>41</volume>: <fpage>279</fpage>–<lpage>281</lpage>.</citation></ref>
<ref id="bibr7-2047487312467876"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lerner</surname><given-names>DJ</given-names></name><name><surname>Kannel</surname><given-names>W</given-names></name></person-group>. <article-title>Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population</article-title>. <source>Am Heart J</source> <year>1986</year>; <volume>111</volume>: <fpage>383</fpage>–<lpage>390</lpage>.</citation></ref>
<ref id="bibr8-2047487312467876"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haeusler</surname><given-names>G</given-names></name></person-group>. <article-title>Potential future developments in the field of antihypertensive drugs</article-title>. <source>Eur Heart J</source> <year>1987</year>; <volume>8</volume>: <fpage>135</fpage>–<lpage>142</lpage>.</citation></ref>
<ref id="bibr9-2047487312467876"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>de Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>2007 guidelines for the management of hypertension</article-title>. <source>Eur Heart J</source> <year>2007</year>; <volume>28</volume>: <fpage>1462</fpage>–<lpage>1538</lpage>.</citation></ref>
<ref id="bibr10-2047487312467876"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Olsen</surname><given-names>MH</given-names></name><name><surname>Cooper</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>1424</fpage>–<lpage>1431</lpage>.</citation></ref>
<ref id="bibr11-2047487312467876"><label>11</label><citation citation-type="journal"><collab>European Association for Cardiovascular Prevention &amp; Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al</collab>. <article-title>ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>1769</fpage>–<lpage>1818</lpage>.</citation></ref>
<ref id="bibr12-2047487312467876"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokgozoglu</surname><given-names>L</given-names></name><name><surname>Bruckert</surname><given-names>E</given-names></name></person-group>. <article-title>Implementation, target population, compliance and barriers to risk guided therapy</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>37</fpage>–<lpage>41</lpage>.</citation></ref>
<ref id="bibr13-2047487312467876"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Svartberg</surname><given-names>J</given-names></name><name><surname>Njølstad</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Change in cardiovascular risk factors in relation to diabetes status: the Tromsø study</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>551</fpage>–<lpage>557</lpage>.</citation></ref>
<ref id="bibr14-2047487312467876"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>DG</given-names></name></person-group>. <article-title>Birth and growth of the European Society of Cardiology</article-title>. <source>Eur Heart J</source> <year>1980</year>; <volume>1</volume>: <fpage>5</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr15-2047487312467876"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lüscher</surname><given-names>TF</given-names></name><name><surname>Gersh</surname><given-names>B</given-names></name><name><surname>Brugada</surname><given-names>J</given-names></name><etal/></person-group><collab>on behalf of the new editorial board</collab>. <article-title>The European Heart Journal goes global – the road ahead of the editorial tam 2009–2011</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation></ref>
<ref id="bibr16-2047487312467876"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lüscher</surname><given-names>TF</given-names></name><name><surname>Dedecke</surname><given-names>S</given-names></name><name><surname>Gersh</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Happy Birthday European Heart Journal – in 30 years from Cinderella to center stage</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>31</volume>: <fpage>1945</fpage>–<lpage>1950</lpage>.</citation></ref>
<ref id="bibr17-2047487312467876"><label>17</label><citation citation-type="other"><comment>Lüscher TF, Gersh B, Hindricks G, et al. The European Heart Journal on the move – can scientific publishing be further improved? <italic>Eur Heart J</italic> 2012 (in press)</comment>.</citation></ref>
<ref id="bibr18-2047487312467876"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saner</surname><given-names>H</given-names></name><name><surname>Wood</surname><given-names>H</given-names></name></person-group>. <article-title>EJCPR is flourishing</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>: <fpage>1</fpage>–<lpage>2</lpage>.</citation></ref>
<ref id="bibr19-2047487312467876"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><etal/></person-group><collab>ESC Committee for Practice Guidelines</collab>. <article-title>ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>2999</fpage>–<lpage>3054</lpage>.</citation></ref>
<ref id="bibr20-2047487312467876"><label>20</label><citation citation-type="journal"><collab>European Society of Gynecology, Association for European Paediatric Cardiology and German Society for Gender Medicine</collab>. <article-title>ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>3147</fpage>–<lpage>3197</lpage>.</citation></ref>
<ref id="bibr21-2047487312467876"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Aboyans</surname><given-names>V</given-names></name><name><surname>Bartelink</surname><given-names>M-L</given-names></name><etal/></person-group>. <article-title>ESC guidelines on the diagnosis and treatment of peripheral artery diseases</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>2851</fpage>–<lpage>2906</lpage>.</citation></ref>
<ref id="bibr22-2047487312467876"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poldermans</surname><given-names>D</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><etal/></person-group><collab>on behalf of the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery; European Society of Cardiology (ESC)</collab>. <article-title>Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>2769</fpage>–<lpage>2812</lpage>.</citation></ref>
<ref id="bibr23-2047487312467876"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perk</surname><given-names>J</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Gohlke</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR)</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>1635</fpage>–<lpage>1701</lpage>.</citation></ref>
<ref id="bibr24-2047487312467876"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moscoso Costa</surname><given-names>F</given-names></name><name><surname>Ferreira</surname><given-names>J</given-names></name><name><surname>Aguiar</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>2544</fpage>–<lpage>2550</lpage>.</citation></ref>
<ref id="bibr25-2047487312467876"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vahanian</surname><given-names>A</given-names></name><name><surname>Alfieri</surname><given-names>O</given-names></name><name><surname>Andreotti</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Guidelines on management of valvular heart disease</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>2451</fpage>–<lpage>2496</lpage>.</citation></ref>
<ref id="bibr26-2047487312467876"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMurray</surname><given-names>JJV</given-names></name><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Anker</surname><given-names>SD</given-names></name><etal/></person-group>. <article-title>ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>1787</fpage>–<lpage>1847</lpage>.</citation></ref>
<ref id="bibr27-2047487312467876"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>James</surname><given-names>SK</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><etal/></person-group><collab>ESC Committee for Practice Guidelines (CPG)</collab>. <article-title>ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>2569</fpage>–<lpage>2619</lpage>.</citation></ref>
<ref id="bibr28-2047487312467876"><label>28</label><citation citation-type="other"><comment>Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. <italic>Eur Heart J</italic> 2012 Aug 24</comment>.</citation></ref>
<ref id="bibr29-2047487312467876"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><etal/></person-group><collab>European Society of Cardiology Committee for Practice Guidelines</collab>. <article-title><italic>European Journal of Cardiovascular Prevention &amp; Rehabilitation</italic> European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2003</year>; <volume>10</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr30-2047487312467876"><label>30</label><citation citation-type="other"><comment>Nallamothu B and Lüscher TF. Moving from impact to influence: measurement and the changing role of medical journals. <italic>Eur Heart J</italic> 2012 [Epub ahead of print]</comment>.</citation></ref>
<ref id="bibr31-2047487312467876"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galiè</surname><given-names>N</given-names></name><name><surname>Hoeper</surname><given-names>MM</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><etal/></person-group><collab>on behalf of the Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT)</collab>. <article-title>Guidelines for the diagnosis and treatment of pulmonary hypertension</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>2493</fpage>–<lpage>2537</lpage>.</citation></ref>
<ref id="bibr32-2047487312467876"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moya</surname><given-names>A</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Ammirati</surname><given-names>F</given-names></name><etal/></person-group><collab>on behalf of the Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS)</collab>. <article-title>Guidelines for the diagnosis and management of syncope</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>2631</fpage>–<lpage>2671</lpage>.</citation></ref>
<ref id="bibr33-2047487312467876"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>G</given-names></name><name><surname>Hoen</surname><given-names>B</given-names></name><name><surname>Tornos</surname><given-names>P</given-names></name><etal/></person-group><collab>ESC Committee for Practice Guidelines</collab>. <article-title>Guidelines on the prevention, diagnosis, and treatment of infective endocarditis and the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>2369</fpage>–<lpage>2413</lpage>.</citation></ref>
<ref id="bibr34-2047487312467876"><label>34</label><citation citation-type="other"><comment>Focus issue on prevention. <italic>Eur Heart J</italic> 2012; 34. Issue 4</comment>.</citation></ref>
<ref id="bibr35-2047487312467876"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kromhout</surname><given-names>D</given-names></name><name><surname>Yasuda</surname><given-names>S</given-names></name><name><surname>Geleijnse</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?</article-title> <source>Eur Heart J</source> <year>2012</year>; <volume>34</volume>: <fpage>436</fpage>–<lpage>444</lpage>.</citation></ref>
<ref id="bibr36-2047487312467876"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Genser</surname><given-names>B</given-names></name><name><surname>Solbernagel</surname><given-names>G</given-names></name><name><surname>de Backer</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Nutrition in cardiovascular disease: a systematic review and metanalysis</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>34</volume>: <fpage>444</fpage>–<lpage>451</lpage>.</citation></ref>
<ref id="bibr37-2047487312467876"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Held</surname><given-names>C</given-names></name><name><surname>Iqbal</surname><given-names>R</given-names></name><name><surname>Lear</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>34</volume>: <fpage>452</fpage>–<lpage>466</lpage>.</citation></ref>
<ref id="bibr38-2047487312467876"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>GN</given-names></name><name><surname>Matthews</surname><given-names>CE</given-names></name><name><surname>Dunstan</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003–2006</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>590</fpage>–<lpage>597</lpage>.</citation></ref>
<ref id="bibr39-2047487312467876"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Schmied</surname><given-names>C</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Risk of sports: do we need a pre-participation screening for competitive and leisure athletes?</article-title> <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>934</fpage>–<lpage>944</lpage>.</citation></ref>
<ref id="bibr40-2047487312467876"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Drezner</surname><given-names>J</given-names></name><name><surname>Basso</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Strategies for the prevention of sudden cardiac death during sports</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>197</fpage>–<lpage>208</lpage>.</citation></ref>
<ref id="bibr41-2047487312467876"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corrado</surname><given-names>D</given-names></name><name><surname>Pelliccia</surname><given-names>A</given-names></name><name><surname>Heidbuchel</surname><given-names>H</given-names></name><etal/></person-group><collab>Section of Sports Cardiology, European Association of Cardiovascular Prevention and Rehabilitation</collab>. <article-title>Recommendations for interpretation of 12-led electrocardiogram in the athlete</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>243</fpage>–<lpage>259</lpage>.</citation></ref>
<ref id="bibr42-2047487312467876"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosterd</surname><given-names>A</given-names></name><name><surname>Senden</surname><given-names>JP</given-names></name><name><surname>Engelfriet</surname><given-names>P</given-names></name></person-group>. <article-title>Preventing sudden cardiac death in athletes: finding the needle in the haystack or closing the barn door?</article-title> <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>194</fpage>–<lpage>196</lpage>.</citation></ref>
<ref id="bibr43-2047487312467876"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahabadi</surname><given-names>AA</given-names></name><name><surname>Massaro</surname><given-names>JM</given-names></name><name><surname>Rosito</surname><given-names>GA</given-names></name><etal/></person-group>. <article-title>Association of pericardial fat, intrathoracic fat and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>850</fpage>–<lpage>856</lpage>.</citation></ref>
<ref id="bibr44-2047487312467876"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klingenberg</surname><given-names>R</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group>. <article-title>Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>2838</fpage>–<lpage>2844</lpage>.</citation></ref>
<ref id="bibr45-2047487312467876"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braunwald</surname><given-names>E</given-names></name></person-group>. <article-title>Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERAL, A to Z, JUPITER, HEART PROTECTION and ASCOT trials</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>430</fpage>–<lpage>432</lpage>.</citation></ref>
<ref id="bibr46-2047487312467876"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sever</surname><given-names>PS</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Chang</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>on behalf of the ASCOT Investigators Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>486</fpage>–<lpage>494</lpage>.</citation></ref>
<ref id="bibr47-2047487312467876"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>NN</given-names></name><name><surname>Azfar</surname><given-names>RS</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><etal/></person-group>. <article-title>Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using general practice research database</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>1000</fpage>–<lpage>1006</lpage>.</citation></ref>
<ref id="bibr48-2047487312467876"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barter</surname><given-names>PJ</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Eriksson</surname><given-names>M</given-names></name><etal/></person-group><collab>on behalf of the ILLUMINATE investigators</collab>. <article-title>Effects of torcetrapib in patients at high risk for coronary events</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>: <fpage>2109</fpage>–<lpage>2122</lpage>.</citation></ref>
<ref id="bibr49-2047487312467876"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simic</surname><given-names>B</given-names></name><name><surname>Hermann</surname><given-names>M</given-names></name><name><surname>Shaw</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Torcetrapib impairs endothelial function in hypertension</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>33</volume>: <fpage>1615</fpage>–<lpage>1624</lpage>.</citation></ref>
<ref id="bibr50-2047487312467876"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vergeer</surname><given-names>M</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>van Leuven</surname><given-names>SI</given-names></name><etal/></person-group>. <article-title>Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials</article-title>. <source>Circulation</source> <year>2008</year>; <volume>118</volume>: <fpage>2515</fpage>–<lpage>2522</lpage>.</citation></ref>
<ref id="bibr51-2047487312467876"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Peloso</surname><given-names>GM</given-names></name><name><surname>Orho-Melander</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study</article-title>. <source>Lancet</source> <year>2012</year>; <volume>380</volume>: <fpage>572</fpage>–<lpage>580</lpage>.</citation></ref>
<ref id="bibr52-2047487312467876"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>EA</given-names></name><name><surname>Roth</surname><given-names>EM</given-names></name><name><surname>Rhyne</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Safety and tolarability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>480</fpage>–<lpage>488</lpage>.</citation></ref>
<ref id="bibr53-2047487312467876"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lüscher</surname><given-names>TF</given-names></name><name><surname>Taddei</surname><given-names>S</given-names></name><name><surname>Kaski</surname><given-names>J-C</given-names></name><etal/></person-group>. <article-title>Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>857</fpage>–<lpage>865</lpage>.</citation></ref>
<ref id="bibr54-2047487312467876"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinshtein</surname><given-names>R</given-names></name><name><surname>Kuvin</surname><given-names>JT</given-names></name><name><surname>Soffler</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts cardiovascular events</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>1142</fpage>–<lpage>1148</lpage>.</citation></ref>
<ref id="bibr55-2047487312467876"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>von Eckardstein</surname><given-names>A</given-names></name><name><surname>Kastelein</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme</article-title>. <source>Eur Heart J</source> <year>2012</year>; <volume>33</volume>: <fpage>1712</fpage>–<lpage>1715</lpage>.</citation></ref>
<ref id="bibr56-2047487312467876"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Le Goff</surname><given-names>W</given-names></name><name><surname>Guerin</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>CETP–at the heart of the action of lipid-modulating therapy with statins, niacin and CETP inhibitors</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>: <fpage>149</fpage>–<lpage>164</lpage>.</citation></ref>
<ref id="bibr57-2047487312467876"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>MJ</given-names></name><name><surname>Ginsberg</surname><given-names>HN</given-names></name><name><surname>Amarenco</surname><given-names>P</given-names></name><etal/></person-group><collab>European Atherosclerosis Society Consensus Panel</collab>. <article-title>Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>1345</fpage>–<lpage>1361</lpage>.</citation></ref>
<ref id="bibr58-2047487312467876"><label>58</label><citation citation-type="other"><comment>Gopinath B, Flood VM, Rochtchina E, et al. Serum homocysteine and folate but not vitamin B12 are predictors of CHD mortality in older adults. <italic>Eur J Cardiovasc Prev Rehabil</italic> 2011 [Epub ahead of print]</comment>.</citation></ref>
<ref id="bibr59-2047487312467876"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antoniades</surname><given-names>C</given-names></name><name><surname>Antonopoulos</surname><given-names>AS</given-names></name><name><surname>Tousoulis</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Homocysteine and coronary atherosclerosis. From folate fortification to the recent clinical trials</article-title>. <source>Eur Heart J</source> <year>2009</year>; <volume>30</volume>: <fpage>6</fpage>–<lpage>15</lpage>.</citation></ref>
<ref id="bibr60-2047487312467876"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cappuccio</surname><given-names>FP</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>D’Elia</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies</article-title>. <source>Eur Heart J</source> <year>2011</year>; <volume>32</volume>: <fpage>1484</fpage>–<lpage>1492</lpage>.</citation></ref>
<ref id="bibr61-2047487312467876"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grobbee</surname><given-names>DE</given-names></name></person-group>. <article-title>The era of preventive cardiology</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>3</fpage>–<lpage>4</lpage>.</citation></ref>
<ref id="bibr62-2047487312467876"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>JL</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name></person-group>. <article-title>Cardiovascular prevention and international health: time for action</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>547</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr63-2047487312467876"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dieren</surname><given-names>S</given-names></name><name><surname>van, Beulens</surname><given-names>JWJ</given-names></name><name><surname>Schouw van der</surname><given-names>YT</given-names></name><etal/></person-group>. <article-title>The global burden of diabetes and its complications: an emerging pandemic</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>3</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr64-2047487312467876"><label>64</label><citation citation-type="journal"><collab>Fifth Joint Task Force of the European Society of Cardiology, European Association of Echocardiography, European Association of Percutaneous Cardiovascular Interventions, et al</collab>. <article-title>European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>585</fpage>–<lpage>667</lpage>.</citation></ref>
<ref id="bibr65-2047487312467876"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanhees</surname><given-names>L</given-names></name><name><surname>Geladas</surname><given-names>N</given-names></name><name><surname>Hansen</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>on behalf of the writing group</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>1005</fpage>–<lpage>1033</lpage>.</citation></ref>
<ref id="bibr66-2047487312467876"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>T</given-names></name><name><surname>Ronghui</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians’ survey in China</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>: <fpage>991</fpage>–<lpage>998</lpage>.</citation></ref>
<ref id="bibr67-2047487312467876"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ambrosio</surname><given-names>G</given-names></name><name><surname>Steinhubl</surname><given-names>S</given-names></name><name><surname>Gresele</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>121</fpage>–<lpage>128</lpage>.</citation></ref>
<ref id="bibr68-2047487312467876"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cavender</surname><given-names>MA</given-names></name><name><surname>Nicholls</surname><given-names>SJ</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name></person-group>. <article-title>Strategies for the development of new PPAR agonists in diabetes</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>Suppl 1</issue>): <fpage>32</fpage>–<lpage>37</lpage>.</citation></ref>
<ref id="bibr69-2047487312467876"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zannad</surname><given-names>F</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name></person-group>. <article-title>Risk-guided therapy: a first step to personalized medicine</article-title>. <source>Eur J Prev Cardiol</source> <year>2012</year>; <volume>19</volume>(<issue>Suppl 2</issue>): <fpage>5</fpage>–<lpage>6</lpage>.</citation></ref>
<ref id="bibr70-2047487312467876"><label>70</label><citation citation-type="other"><comment>Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. <italic>Eur J Prev Cardiol</italic> 2012 [Epub ahead of print]</comment>.</citation></ref>
<ref id="bibr71-2047487312467876"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>EUROASPIRE III: a survey on the life style, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>121</fpage>–<lpage>137</lpage>.</citation></ref>
<ref id="bibr72-2047487312467876"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 countries</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>530</fpage>–<lpage>540</lpage>.</citation></ref>
<ref id="bibr73-2047487312467876"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Corra</surname><given-names>U</given-names></name><name><surname>Benzer</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>1</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr74-2047487312467876"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neubeck</surname><given-names>L</given-names></name><name><surname>Redfern</surname><given-names>J</given-names></name><name><surname>Fernandez</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Telehealth interventions for secondary prevention of coronray heart disease: a systematic review</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>281</fpage>–<lpage>289</lpage>.</citation></ref>
<ref id="bibr75-2047487312467876"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Agostoni</surname><given-names>P</given-names></name><name><surname>Cohen-Solal</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>249</fpage>–<lpage>267</lpage>.</citation></ref>
<ref id="bibr76-2047487312467876"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>JM</given-names></name><name><surname>Ekelund</surname><given-names>U</given-names></name><name><surname>Besson</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Assessment of physical activity – a review of methodologies with reference to epidemiological research: a report by the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>127</fpage>–<lpage>139</lpage>.</citation></ref>
<ref id="bibr77-2047487312467876"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Metsios</surname><given-names>GS</given-names></name><name><surname>Stavropoulos-Kalinoglou</surname><given-names>A</given-names></name><name><surname>Panoulas</surname><given-names>VF</given-names></name><etal/></person-group>. <article-title>Association of physically inactivity with increased cardiovascular risk in patients with rheumatoid arthritis</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>188</fpage>–<lpage>194</lpage>.</citation></ref>
<ref id="bibr78-2047487312467876"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cooney</surname><given-names>MT</given-names></name><name><surname>Dudina</surname><given-names>A</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>How much HDL cholesterol add to risk estimation? A report from the SCORE investigators</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>: <fpage>304</fpage>–<lpage>314</lpage>.</citation></ref>
<ref id="bibr79-2047487312467876"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>M</given-names></name><name><surname>Zethelius</surname><given-names>B</given-names></name><name><surname>Eeg-Olofsson</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2011</year>; <volume>18</volume>: <fpage>97</fpage>–<lpage>105</lpage>.</citation></ref>
<ref id="bibr80-2047487312467876"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Dieren</surname><given-names>S</given-names></name><name><surname>Beulens</surname><given-names>JW</given-names></name><name><surname>van der Schouw</surname><given-names>YT</given-names></name><etal/></person-group>. <article-title>The global burden of diabetes and its complications: an emerging pandemic</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>Suppl 1</issue>): <fpage>S3</fpage>–<lpage>S8</lpage>.</citation></ref>
<ref id="bibr81-2047487312467876"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friis-Moller</surname><given-names>N</given-names></name><name><surname>Thiebaut</surname><given-names>R</given-names></name><name><surname>Reiss</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>: <fpage>491</fpage>–<lpage>501</lpage>.</citation></ref>
</ref-list>
</back>
</article>